预测模型研究新型结核药物方案的治疗缩短潜力:走向临床前数据整合
该研究在小鼠结核感染模型中评估BPaMZ与BPaL方案不同疗程的复发关系,并以HRZE为标准对照,结合数学模型预测治愈概率。结果显示BPaMZ仅6周即治愈全部小鼠,而BPaL 13周和HRZE 24周均未达100%治愈;模型预测95%治愈概率分别需1.6、4.3和7.9个月。研究支持BPaMZ较BPaL和HRZE具有更强缩短疗程能力,并倡导整合临床前数据以优化临床结局预测。
要点
- 小鼠模型中BPaMZ 6周治愈全部小鼠,BPaL 13周和HRZE 24周未达100%治愈。
- 模型预测95%治愈概率:BPaMZ 1.6个月、BPaL 4.3个月、HRZE 7.9个月。
- 建议整合已发表临床前数据至数学模型,以辅助预测临床结局。
核心结论
- BPaMZ方案较BPaL和HRZE具有更强缩短结核疗程的潜力。
- 整合临床前数据至数学模型有助于预测临床结局并克服外推局限。
研究设计与样本
- 研究采用结核分枝杆菌感染小鼠模型,治疗最长13周,停药后12周评估治愈率。
- 方案包括BPaMZ(贝达喹啉+普托马尼+莫西沙星+吡嗪酰胺)、BPaL(贝达喹啉+普托马尼+利奈唑胺)及对照HRZE(异烟肼+利福平+吡嗪酰胺+乙胺丁醇)。
- 结合数学模型预测治愈概率与疗程关系。
主要发现
- BPaMZ治疗6周即可使全部小鼠达到治愈。
- BPaL治疗13周和HRZE治疗24周均未达到100%治愈率。
- 数学模型预测95%治愈概率所需时间:BPaMZ 1.6个月、BPaL 4.3个月、HRZE 7.9个月。
临床怎么用
- BPaMZ方案在动物模型中显示显著缩短疗程的优势,支持进一步临床开发。
- 临床前数据可通过数学模型整合,辅助优化临床试验设计和疗程预测。
局限性
- 研究基于小鼠模型,结果外推至人类存在局限性。
- 作者倡导整合已发表临床前数据以克服外推局限,但未具体描述整合方法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Given the persistently high global burden of tuberculosis, effective and shorter treatment options are needed. We explored the relationship between relapse and treatment length as well as interregimen differences for 2 novel antituberculosis drug regimens using a mouse model of tuberculosis infection and mathematical modeling. METHODS: Mycobacterium tuberculosis-infected mice were treated for up to 13 weeks with bedaquiline and pretomanid combined with moxifloxacin and pyrazinamide (BPaMZ) or linezolid (BPaL). Cure rates were evaluated 12 weeks after treatment completion. The standard regimen of isoniazid, rifampicin, pyrazinamide, and ethambutol (HRZE) was evaluated as a comparator. RESULTS: Six weeks of BPaMZ was sufficient to achieve cure in all mice. In contrast, 13 weeks of BPaL and 24 weeks of HRZE did not achieve 100% cure rates. Based on mathematical model predictions, 95% probability of cure was predicted to occur at 1.6, 4.3, and 7.9 months for BPaMZ, BPaL, and HRZE, respectively. CONCLUSION: This study provides additional evidence for the treatment-shortening capacity of BPaMZ over BPaL and HRZE. To optimally use preclinical data for predicting clinical outcomes, and to overcome the limitations that hamper such extrapolation, we advocate bundling of available published preclinical data into mathematical models.
引用
- Mudde SE, Ayoun Alsoud R, van der Meijden A, et al. Predictive Modeling to Study the Treatment-Shortening Potential of Novel Tuberculosis Drug Regimens, Toward Bundling of Preclinical Data. J Infect Dis. 2022. PMID: 33606880. doi:10.1093/infdis/jiab101
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。